Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: An in vitro and in vivo study

Journal of Orthopaedic Research

Volumn 24, Issue 8, 2006, Pages 1622-1640

  Kälicke, Thomas ^a   Schierholz, Jörg ^b   Schlegel, Urs ^c   Frangen, Thomas Manfred ^a   Köller, Manfred ^a   Printzen, Gert ^d   Seybold, Dominik ^a   Klöckner, Stefan ^b   Muhr, Gert ^a   Arens, Stephan ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CENTER OF ADVANCED EUROPEAN STUDIES AND RESEARCH CAESAR   (Germany)

^c AO RESEARCH INSTITUTE   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antibiotic; Antiseptic; Infection; Plate osteosynthesis; PLLA

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; FUSIDIC ACID; OCTENIDINE; POLYLACTIDE; RIFAMPICIN; SODIUM CHLORIDE; TITANIUM; TRICLOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; ASEPSIS; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BACTERIUM CONTAMINATION; BIODEGRADABILITY; BONE INFECTION; BONE PLATE; CONTROLLED STUDY; DEGRADATION; DRUG EFFICACY; DRUG RELEASE; ELUTION; EQUIPMENT DESIGN; EXPERIMENTAL DESIGN; FISHER EXACT TEST; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFECTION RATE; INFECTION RESISTANCE; INFORMATION PROCESSING; INOCULATION; MATERIAL COATING; NONHUMAN; OSTEOSYNTHESIS MATERIAL; PRIORITY JOURNAL; PROVOCATION TEST; QUANTITATIVE ANALYSIS; RABBIT; REPRODUCIBILITY; SOFT TISSUE INFECTION; STANDARDIZATION; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ABSORBABLE IMPLANTS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; COATED MATERIALS, BIOCOMPATIBLE; FRACTURE FIXATION, INTERNAL; MATERIALS TESTING; MICROBIOLOGICAL TECHNIQUES; POLYESTERS; PROSTHESIS-RELATED INFECTIONS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TITANIUM;

EID: 33746936052     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20193     Document Type: Article

References (84)

1. Bach AW, Hansen ST. 1989. Plates versus external fixation in severe open tibial fractures. Clin Orthop 241:89-94.
2. Matter P, Schütz M, Bühler M, et al. 1994. Klinische Ergebnisse mit der Limited Contact DCP-Platte aus Titan: ein prospektive Studie mit 500 Fällen. Z Unfallchir Vers Med 87:6-13.
3. Boxma H, Broekhuizen T, Patka P, et al. 1996. Randomized controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the Dutch Trauma Trial. Lancet 347:1133-1137.
4. Gustillo RB, Mendoza RM, Williams DM. 1984. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma 24:742-746.
5. Hansis M, Arens S. 1996. Prophylaktische und therapeutische Anwendung von Antibiotika in der Unfallchirurgie. Unfallchirurg 99:316-322.
6. Miclau T, Martin RE. 1997. The evolution of modern plate osteosynthesis. Injury 28:3-6.
7. Nast-Kolb D, Betz A, Schweiberer L. 1991. Der Wandel in der Unfallchirurgie der letzten 10 Jahre - ein Beitrag zur Infektionsprophylaxe. Chirurg 62:846-851.
8. Perren SM. 1991. The concept of biological plating using the limited contact-dynamic compression plate (LC-DCP). Injury 22:1-10.
9. Arens S, Kutscha-Lissberg F, Hebler U, et al. 2002. Pyogenic infection following arthroplasty: incidence and economic consequences. Deutsche Gesellschaft für Chirurgie Kongressband 119:738-742.
10. Stickler DJ, McLean RJ. 1995. Biomaterials associated infections: the scale of the problem. Cells Materials 5:167-182.
11. Sugarman B, Young EJ. 1989. Infections associated with prosthetic devices: magnitude of the problem. Inf Dis Clin North Am 3:187-198.
12. Gristina AG. 1987. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 237:1588-1595.
13. Lew DP, Waldvogel FA. 1997. Osteomyelitis. N Engl J Med 336:999-1006.
14. Sugarman B. 1986. Infection and prosthetic devices. Am J Med 81:78-84.
15. Claes L. 1997. Die grundlagennahe chirurgische Forschung. In: Oestern HJ, Probst J, editors. Unfallchirurgie in Deutschland. Bilanz und Perspektiven. Berlin: Springer; p 165-173.
16. Brennan PJ, DeGirolano MP. 1989. Musculoskeletal infections immunocompromised hosts. Orthop Clin North Am 12:389-399.
17. Kossmann T, Morganti-Kossmann MC, Smith P, et al. 1993. Opportunistische Infektionen bei Patienten mit gestörter Abwehrlage. Unfallchirurg 96:176-180.
18. Williams DF. 1996. Introduction: implantable materials and infection. Injury 27:1-4.
19. Elek SD, Conen PE. 1957. The virulence of staphylococcus pyogens for man. Br J Exp Path 38:573-586.
20. Barton AJ, Sagers RD, Pitt WG. 1996. Measurement of bacterial growth rates on polymers. J Biomed Mater Res 32:271-278.
21. Gristina AG, Naylor PT, Myrvik QN. 1991. Mechanisms of musculoskeletal sepsis. Orthop Clin North Am 22:363-371.
22. Printzen G. 1996. Relevance, pathogenicity and virulence of microorganisms in implant related infections. Injury 27: 9-15.
23. Naylor P, Jennings R, Myrvik Q, et al. 1998. Antibiotic sensitivity of biomaterial adherent Staphylococcus epidermidis. Orthop Trans 12:524-525.
24. Shanbhag A, Yang J, Lilien J, et al. 1992. Decreased neutrophil respiratory burst on exposure to cobalt-chrome alloy and polystyrene in vitro. J Biomed Mater Res 26: 185-195.
25. Zimmerli W, Lew PD, Waldvogel FA. 1984. Pathogenesis of foreign body infections: evidence for local granulocyte defect. J Clin Invest 73:1191-1200.
26. Gristina AG, Webb LX, Barth E. 1989. Microbial adhesion, biomaterials and man. In: Coombs R, Fitzgerald R, editors. Infection in orthopaedic patient. London: Butterworths; p 30-40.
27. Nichols WW, Dorrington SM, Slack MPE. 1989. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol 135:1291-1301.
28. Schierholz JM, Beuth J. 2001. Implant infections: a haven for opportunistic bacteria. J Hosp Infect 49:87-93.
29. Schierholz JM, Beuth J. 2000. Sophisticated medical devices as local drug-delivery-systems. Med Device Technol 11:12-17.
30. Schierholz JM, Steinhauser H, Rump AF, et al. 1997. Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features. Biomaterials 18:839-844.
31. Blaha JD, Calhoun JH, Nelson CL, et al. 1993. Comparison of the clinical efficacy and tolerance of gentamicin PMMA beads on surgical wire versus combined and systemic therapy of osteomyelitis. Clin Orthop 295:8-12.
32. Schierholz JM, Puverer G. 1998. Investigation of a rifampicin, fusidic-acid and mupirocin releasing silicone catheter. Biomaterials 19:2065-2074.
33. Arens S, Schlegel U, Printzen G, et al. 1996. Influence of the materials for fracture fixation implants on the development of local infection. An experimental study of steel versus titanium DC-Plates in rabbits. J Bone Joint Surg [Br] 78-B:647-651.
34. Arens S, Eijer H, Schlegel U, et al. 1999. Influence of the design for fixation implants on local infection. An experimental study of DC-Plates vs. Point-Contact-Fixators in rabbits. J Orthop Trauma 13:470-476.
35. Arens S, Kraft C, Schlegel U, et al. 1999. Susceptibility to local infection in biological internal fixation. Experimental study of open vs. minimally invasive plate osteosynthesis (MIPO) in rabbits. Arch Orthop Trauma Surg 119:82-85.
36. Melcher GA, Claudi B, Schlegel U, et al. 1994. Influence of type of medullary nail on the development of local infection. An experimental study of solid and slotted nails in rabbits. J Bone Joint Surg [Br] 76B:955-959.
37. Flecknell PA. 1993. Anaesthesia of animals for biomedical research. Br J Anaesth 71:885-894.
38. Armitage P. 1971. Sequential methods. In: Brown A, editor Statistical methods in medical research. 2. Auflage. Oxford and Edinburgh: Blackwell Scientific; p 415-425.
39. 50: a critique. Biometrics 6:413-423.
40. Bross I. 1952. Sequential medical plans. Biometrics 8:188-205.
41. Cavalli-Sforza L. 1964. Grundbegriffe der Biometrie, insbesondere der statistischen Methoden bei der Wertebemessung biologisch wirksamer Substanzen. Stuttgart: Gustav Fischer Verlag.
42. Feder PI, Hobson DW, Olson CT, et al. 1991. Stagewise, adaptive dose allocation for quantal response dose-response studies. Neurosci Biobehav Rev 15:109-114.
43. Kälicke T, Sprutacz O, Schlegel U, et al. 2004. Einfluss der lokalen Applikation von basic Fibroblast Growth Factor auf die lokale Infektionsresistenz nach standardisiertem, geschlossenem Weichteiltrauma. Eine experimentelle Studie an Ratten. Unfallchirurg 107:211-218.
44. Kälicke T, Schlegel U, Printzen G, et al. 2003. Influence of a standardized closed soft tissue trauma on resistance to local infection. An experimental study in rats. J Orthop Res 21:373-378.
45. Spicer CC. 1962. Some new closed sequential designs for clinical trials. Biometrics 18:203-211.
46. Ziegler WJ. 1976. Zum Problem der Optimumeigenschaften von SPR-Tests. In: Ziegler WJ, editor. Contributions to applied statistics. Basel and Stuttgart: Birkhauser Verlag; p 257-262.
47. Dixon WJ, Mood AM. 1948. A method for obtaining and analyzing sensitive data. J Am Stat Assoc 43:109-126.
48. Freedman KB, Bernstein J. 1999. Sample size and statistical power in clinical orthopaedic research. J Bone Joint Surg [Am] 81-A:1454-1460.
49. Reed LJ, Münch H. 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493-497.
50. Cornell CN, Tyndall D, Waller S, et al. 1993. Treatment of experimental osteomyelitis with antibiotic-impregnated bone graft substitutes. J Orthop Res 11:619-626.
51. Korkusuz F, Uchida A, Shinto Y, et al. 1993. Experimental implant-related osteomyelitis treated by antibiotic-calcium hydroxyapatite ceramic composites. J Bone Joint Surg [Br] 75-B:111-114.
52. Lambotte JC, Thomazeau H, Cathelineau G, et al. 1998. Tricalcium phosphate an antibiotic carrier: a study focused on experimental osteomyelitis in rabbits. Chirurgie 123:572-579.
53. Shinto Y, Uchida A, Korkusuz F, et al. 1992. Calcium hydroxyapatite ceramic used as a delivery system for antibiotics. J Bone Joint Surg [Br] 74-B:600-604.
54. Yamashita Y, Uchida A, Yamakawa T, et al. 1998. Treatment of chronic osteomyelitis using calcium hydroxyapatite ceramic implants impregnated with antibiotic. Int Orthop 22:247-251.
55. Yu D, Wong J, Matsuda Y, et al. 1992. Self-setting hydroxyapatite cement: a novel skeletal drug-delivery system for antibiotics. J Pharm Sci 81:521-529.
56. Aimin C, Chunlin H, Juliang B, et al. 1999. Antibiotic loaded chitosan bar. An in vitro, in vivo study of a possible treatment for osteomyelitis. Clin Orthop 366: 239-247.
57. Garvin KL, Miyano JA, Robinson D, et al. 1994. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis. J Bone Joint Surg [Am] 76-A:1500-1506.
58. Gürsel I, Korkusuz F, Türesin F, et al. 2001. In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials 22:73-80.
59. Kanellakopoulou K, Galanakis N, Giamarellos-Bourboulis EJ, et al. 2000. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactid acid polymer releasing pefloxacin. J Antimicrob Chemother 46:311-314.
60. Laurencin CT, Gerhart T, Witscheger P, et al. 1993. Bioerodible polyanhydrides for antibiotic drug delivery: in vivo osteomyelitis. J Orthop Res 11:256-262.
61. Leyh RG, Bartels C, Sievers HH. 1999. Adjuvant treatment of deep sternal wound infection with collagenous gentamicin. Ann Thorac Surg 68:1648-1651.
62. Lucke M, Schmidmaier G, Sadoni S, et al. 2003. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone 32:521-531.
63. Overbeck JP, Winckler ST, Meffert R, et al. 1995. Penetration of ciprofloxacin into bone: a new bioabsorbable implant. J Invest Surg 8:155-162.
64. Sanchez E, Baro M, Soriano I, et al. 2001. In vivo-in vitro study of biodegradable and osteointegrable gentamicin bone implants. Eur J Pharm Biopharm 52:151-158.
65. Sasaki S, Ishii Y. 1999. Apatite cement containing antibiotics: efficacy in treating experimental osteomyelitis. J Orthop Sci 4:361-369.
66. Schmidt C, Wenz R, Nies B, et al. 1995. Antibiotic in vivo/in vitro release, histocompatibility and biodegradation of gentamicin implants based on lactid acid polymers and coploymers. J Control Release 37:83-94.
67. Soriano I, Evora C. 2000. Formulation of calcium phosphates/ poly(D,L-lactide) blends containing gentamicin for bone implantation. J Control Release 68:121-134.
68. Wei G, Kotoura Y, Oka M, et al. 1991. A bioabsorbable delivery system for antibiotic treatment of osteomyelitis. J Bone Joint Surg [Br] 73-B:246-252.
69. Yagmurlu MF, Korkusuz F, Gürsel I, et al. 1999. Sulbactam-cefoperazone polyhydroxybutyrate-co-hydroxy-valerate (PHBV) local antibiotic delivery system: in vivo effectiveness and biocompatibility in the treatment of implant-related experimental osteomyelitis. J Biomed Mater Res 46:494-503.
70. Schmidmaier G, Wildemann B, Bail H. 2001. Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-β1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. Bone 28:341-350.
71. Schierholz JM, Rump A, Pulverer G. 1997. New anti-infectious biomaterials - ciprofloxacin containing polyurethans as potential drug delivery systems to prevent foreign-body infection. Arzneim Forsch Drug Res 47: 70-74.
72. Price JS, Tencer AF, Arm DM. 1996. Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res 30:281-286.
73. Baro M, Sanchez E, Delgado A, et al. 2002. In vitro-in vivo characterization of gentamicin bone implants. J Controlled Release 83:353-364.
74. Tas C, Kozluca A, Onur MA, et al. 1998. In vivo degradation and release kinetics of chloramphenicol-loade poly(D,L)-lactide sponges. Tissue Eng 4:353-363.
75. Barth E, Myrvik QM, Wagner W, et al. 1989. In vitro and in vivo comparative colonization of Staphylococcus aureus and Staphylococcus epidermidis on orthopaedic implant materials. Biomaterials 10:325-328.
76. Dougherty SH, Simmons RL. 1989. Endogenous factors contributing to prosthetic device infections. Infect Dis Clin North Am 3:199-209.
77. Gristina AG, Costerton JW. 1985. Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis. J Bone Joint Surg [Am] 67A:264-273.
78. Merrit K, Gaind A, Anderson JM. 1998. Detection of bacterial adherence on biomedical polymers. J Biomed Mater Res 39:415-422.
79. Galandiuk S, Wrightson WR, Young S, et al. 1997. Absorbable, delayed-release antibiotic beads reduce surgical wound infection. Am Surg 63:831-835.
80. Gollwitzer H, Ibrhim K, Meyer H, et al. 2003. Antibacterial poly(D,L.lactic acid) coating of medical implants using a biodegradable drug delivery technology. J Antimicrob Chemother 51:585-591.
81. Joosten U, Joist A, Frebel T, et al. 2004. Evaluation of an in situ setting injectable calcium phosphate as new carrier material for gentamicin in the treatment of chronic osteomyelitis: studies in vitro and in vivo. Biomaterials 25:4287-4295.
82. Nelson CL, McLaren SG, Skinner RA, et al. 2002. The treatment of experimental osteomyelitis by surgical debridement and implantation of calcium sulfate tobramycin pellets. J Orthop Res 20:643-647.
83. Ramchandani M, Robinson D. 1999. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J Controlled Release 54:167-175.
84. Darouiche RO, Farmer J, Chaput C, et al. 1998. Anti-infective efficacy of antiseptic-coated intramedullary nails. J Bone Joint Surg [Am] 80-A:1336-1340.